Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Osteopore Ltd. ( (AU:OSX) ) has shared an announcement.
Osteopore Ltd. has announced the recruitment of its first patient in a clinical study at Queensland Children’s Hospital, aiming to treat temporal hollowing in children following cranial vault remodelling surgery. The study will explore the use of a 3D-printed, patient-specific scaffold combined with bone marrow aspirate and platelet-rich fibrin to restore the frontotemporal contour. This initiative underscores Osteopore’s commitment to advancing regenerative medicine solutions, particularly for pediatric patients, and positions the company as a leader in innovative medical technology.
More about Osteopore Ltd.
Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia. It specializes in commercializing products that facilitate natural bone healing across various therapeutic areas. The company utilizes patented technology to create micro-structured scaffolds for bone regeneration using 3D printing and bioresorbable materials.
Average Trading Volume: 2,150,114
Technical Sentiment Signal: Sell
Current Market Cap: A$3.52M
Find detailed analytics on OSX stock on TipRanks’ Stock Analysis page.